AbbVie Inc (AbbVie) develops pharmaceuticals and biopharmaceuticals for the treatment of chronic rheumatological, gastroenterological, dermatological, neurological, viral, and metabolic diseases; cancer and other serious autoimmune diseases; and health conditions. It also offers patient support programs. The company operates through one business segment: research and development, manufacturing, commercialization and sale of innovative medicines and therapies.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

AbbVie carries out R&D efforts for the development of new products and improvement of existing products. Its pipeline includes advanced drugs that demonstrate both strong clinical performance and economic value. The company is developing products in immunology, oncology, aesthetics, neuroscience and eye care, and a few other conditions. It is also focusing on reviewing its compounds, existing medicines, and pipeline assets to evaluate their efficacy as potential treatments. The company interacts with global health authorities, government health officials, universities, and other biopharmaceutical companies to help address the medical impact of the pandemic. AbbVie's pipeline spans immunological, oncological, aesthetics and neuroscience compounds and others under development for cystic fibrosis and women's health. Among these pipeline programs, around 90 compounds are in mid- to late-stage development phases. In FY2023, it spent US$7,675 million on R&D, which as a percentage of its revenue, stood at 14%. Some of its major pipeline products include BOTOX, ABBV-552, Bonte, Imbruvica, Epcoritamab, Telisotuzumab vedotin, Rinvoq, and ABBV-916. It has R&D facilities in the US; and Ludwigshafen, Germany. AbbVie works in collaboration with other pharmaceutical and biotechnology companies and academic institutions to identify and prioritize promising novel treatments that complement and enhance its existing portfolio. It owns numerous US and foreign patents covering various drugs and their uses, product manufacturing processes and pharmaceutical formulations.